SPMS
MCID: SCN036
MIFTS: 51

Secondary Progressive Multiple Sclerosis (SPMS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 54 15 17
Multiple Sclerosis, Secondary Progressive 71
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
SNOMED-CT 67 425500002
UMLS 71 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to allergic encephalomyelitis and primary progressive multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dimethyl fumarate and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are homeostasis/metabolism and immune system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 513)
# Related Disease Score Top Affiliating Genes
1 allergic encephalomyelitis 31.4 MBP CCL2
2 primary progressive multiple sclerosis 31.1 S100B MMP9 MBP IL4 IL10 IFNB1
3 exanthem 30.7 IL10 IFNG CD40LG ALB
4 macular retinal edema 30.6 IFNB1 CCL2 ALB
5 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL17A IL10 IFNG
6 optic neuritis 30.6 MBP IL10 CXCR3 CXCL10 CCR5 BDNF
7 progressive multifocal leukoencephalopathy 30.6 MBP IFNB1 CD40LG
8 acute cystitis 30.5 IL10 CD40LG CCL2 ALB
9 pericarditis 30.5 IFNG CD40LG ALB
10 encephalitis 30.5 IL4 IL10 IFNB1 CXCL10 CD40LG CCR5
11 relapsing-remitting multiple sclerosis 30.5 RORC NGF MMP9 MBP IL4 IL17A
12 nervous system disease 30.4 MMP9 IFNG CXCR3 BDNF ALB
13 chickenpox 30.2 IL4 IL10 IFNG IFNB1 CD40LG ALB
14 bacterial infectious disease 30.2 IL17A IL10 IFNG IFNB1 CD40LG CCL2
15 tetanus 30.2 MBP IL4 IL10 IFNG CD40LG ALB
16 neuromyelitis optica 30.2 S100B MBP IL4 IL17A CXCL10 CD40LG
17 arthritis 30.2 MMP9 IL4 IL17A IL10 IFNG CCR2
18 neutropenia 30.1 IL10 IFNG CD40LG ALB
19 neuritis 30.1 MMP9 MBP IL4 IL10 IFNG CXCL10
20 proteasome-associated autoinflammatory syndrome 1 30.1 MMP9 IL4 IL17A IL10 IFNG CXCL10
21 multiple sclerosis 29.8 NGF MMP9 MBP IL4 IL17A IL10
22 autoimmune disease 29.7 MMP9 MBP IL4 IL17A IL10 IFNG
23 demyelinating disease 29.6 NGF MMP9 MBP IL4 IL17A IL10
24 inflammatory bowel disease 29.3 RORC MMP9 IL4 IL17A IL10 IFNG
25 scapuloperoneal myopathy, x-linked dominant 11.6
26 scapuloperoneal myopathy 11.5
27 tropical endomyocardial fibrosis 10.7 IL4 IL10
28 prolapse of lacrimal gland 10.7 MMP9 CD40LG
29 lentigo maligna melanoma 10.7 S100B MMP9
30 folliculotropic mycosis fungoides 10.7 CXCR3 CCR3
31 cork-handlers' disease 10.7 CD40LG ALB
32 suppurative uveitis 10.7 IL17A CD40LG
33 acute transverse myelitis 10.7 MMP9 IL10
34 mycetoma 10.6 MMP9 IL17A IL10
35 nerve fibre bundle defect 10.6 CD40LG BDNF
36 fournier gangrene 10.6 CD40LG ALB
37 chromoblastomycosis 10.6 MMP9 IL4 CXCR3
38 palladium allergic contact dermatitis 10.6 IL17A IL10 CCL2
39 neurosyphilis 10.6 IL17A IL10 CXCL10
40 metal allergy 10.6 IL4 IL17A IL10
41 brawny scleritis 10.6 IFNG CD40LG
42 sydenham chorea 10.6 CXCL10 BDNF
43 chronic meningitis 10.6 MMP9 CD40LG ALB
44 parotitis 10.6 MMP9 CD40LG ALB
45 chronic graft versus host disease 10.6 IL10 IFNG ALB
46 dacryoadenitis 10.6 IL4 IL17A IL10
47 mikulicz disease 10.6 IL4 IL10 CD40LG
48 trichinosis 10.6 IL4 IL10 CD40LG
49 klebsiella pneumonia 10.6 IL17A CD40LG ALB
50 heterophyiasis 10.6 CD40LG ALB

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 ALB BDNF CCR2 CCR3 CCR5 CD40LG
2 immune system MP:0005387 10.41 ALB CCL2 CCL21 CCR2 CCR3 CCR5
3 cellular MP:0005384 10.39 ALB BDNF CCR2 CCR3 CCR5 CD40LG
4 hematopoietic system MP:0005397 10.39 CCL21 CCR2 CCR3 CCR5 CD40LG CXCL10
5 mortality/aging MP:0010768 10.31 ALB BDNF CCR2 CCR5 CD40LG CXCL10
6 cardiovascular system MP:0005385 10.26 ALB CCR2 CCR5 CD40LG CXCL10 CXCR3
7 digestive/alimentary MP:0005381 10.24 ALB BDNF CCR2 CCR5 IFNG IL10
8 endocrine/exocrine gland MP:0005379 10.18 ALB BDNF CCL21 CD40LG IFNG IL10
9 nervous system MP:0003631 10.15 BDNF CCR2 CCR5 CD40LG CXCL10 IFNB1
10 integument MP:0010771 10.11 BDNF CD40LG IFNG IL10 IL17A IL4
11 neoplasm MP:0002006 10.01 ALB CCR2 CCR5 CXCR3 IFNB1 IFNG
12 no phenotypic analysis MP:0003012 9.97 BDNF CCR2 IFNB1 IFNG IL10 IL17A
13 normal MP:0002873 9.96 ALB BDNF CXCR3 IFNB1 IFNG IL10
14 renal/urinary system MP:0005367 9.76 ALB CCR2 CD40LG CXCR3 IFNG IL17A
15 respiratory system MP:0005388 9.61 BDNF CCR2 CCR3 CXCR3 IFNG IL10
16 vision/eye MP:0005391 9.32 BDNF CCL21 CCR2 CCR5 IFNG IL10

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
4
Natalizumab Approved, Investigational Phase 4 189261-10-7
5
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
6
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
7 Dermatologic Agents Phase 4
8 Anti-Infective Agents Phase 4
9 Interferon-beta Phase 4
10 Antiviral Agents Phase 4
11 Potassium Channel Blockers Phase 4
12 Adrenocorticotropic Hormone Phase 4
13 Melanocyte-Stimulating Hormones Phase 4
14 beta-Endorphin Phase 4
15 Endorphins Phase 4
16 Hormones Phase 4
17 Anti-Inflammatory Agents Phase 4
18 glucocorticoids Phase 4
19 Hormone Antagonists Phase 4
20 Antineoplastic Agents, Hormonal Phase 4
21
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
22
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
23
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
24
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
25
Chlorpheniramine Approved Phase 2, Phase 3 132-22-9, 113-92-8 2725
26
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
27 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
28
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
29
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
30
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
31
rituximab Approved Phase 3 174722-31-7 10201696
32
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
33
Mesna Approved, Investigational Phase 3 3375-50-6 598
34
Etoposide Approved Phase 3 33419-42-0 36462
35
Carmustine Approved, Investigational Phase 3 154-93-8 2578
36
Lenograstim Approved, Investigational Phase 3 135968-09-1
37
Melphalan Approved Phase 3 148-82-3 460612 4053
38
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
39
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
40
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
41
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
42
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
43
Histamine Approved, Investigational Phase 3 51-45-6 774
44
Lenalidomide Approved Phase 3 191732-72-6 216326
45
Ixazomib Approved, Investigational Phase 3 1072833-77-2
46
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
47
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
48
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
49
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
50 Alpha-lipoic Acid Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 147)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis Completed NCT02683863 Phase 4 BG00012 (DMF) (Tecfidera®.)
2 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
3 Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone Completed NCT01142466 Phase 4 Interferon beta-1a (Rebif)
4 An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830 Completed NCT00915460 Phase 4 Interferon beta-1a (Avonex)
5 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
6 A Randomized, Single-Blind, Clinical Study to Assess Food Occlusion Efficacy of a Marketed Denture Adhesive in Healthy, Edentulous Subjects Completed NCT03709810 Phase 4
7 Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Recruiting NCT04178005 Phase 4 Cladribine
8 Cladribine Tablets: Collaborative Study to Evaluate the Impact On Central Nervous System Biomarkers in Multiple Sclerosis Recruiting NCT03963375 Phase 4 Cladribine
9 Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS Active, not recruiting NCT02446886 Phase 4 Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)
10 Phase IV Study of Oral Prednisone Taper vs. Placebo Following Intravenous Steroids for the Treatment of Acute Relapses in Multiple Sclerosis Within the Ticino Cohort Terminated NCT01411514 Phase 4 Prednisone;Placebo
11 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
12 Lipoic Acid for Neuroprotection in Secondary Progressive MS Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
13 A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Completed NCT01433497 Phase 3 Masitinib;Placebo
14 Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate Completed NCT03315923 Phase 2, Phase 3 Rituximab;Glatiramer Acetate
15 A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
16 A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study Completed NCT00241254 Phase 3 Cyclophosphamide (drug);Methylprednisolone (drug)
17 Double-blind Extension of the Study 27025 (REFLEX) to Obtain Long-term Follow-up Data in Patients With Clinically Definite MS and Patients With a First Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New Formulation (REFLEXION) Completed NCT00813709 Phase 3 RNF;RNF;RNF;Placebo
18 A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC) Completed NCT00988208 Phase 3 Lenalidomide;Docetaxel;Prednisone;Placebo
19 Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT) Completed NCT02322320 Phase 3 Lenalidomide
20 Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years Recruiting NCT03653273 Phase 3 DMT continuation
21 A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability Recruiting NCT03387670 Phase 3 Simvastatin;Placebo
22 A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Recruiting NCT02057159 Phase 2, Phase 3
23 A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis Recruiting NCT04411641 Phase 3 SAR442168;Placebo to match SAR442168
24 A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI) Recruiting NCT04047628 Phase 3
25 Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial Recruiting NCT02858258 Phase 3 R-CHOP/R-DHAP;Ibrutinib (Induction);ASCT conditioning;Ibrutinib (Maintenance)
26 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312. Active, not recruiting NCT01665144 Phase 3 BAF312;Placebo
27 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients Not yet recruiting NCT03710655 Phase 3 Apitox - pure honeybee toxin;Placebo
28 Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I) Not yet recruiting NCT03720041 Phase 3 R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm;R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm;R2: Lenalidomide plus placebo maintenance;R2: Lenalidomide + ixazomib maintenance
29 A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3 MBP8298
30 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension Terminated NCT01416181 Phase 3 natalizumab;Placebo
32 A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis Terminated NCT00146159 Phase 3 Mitoxantrone
33 An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
34 A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis Withdrawn NCT00313976 Phase 3 Interferon beta-1b (Betaferon/Betaseron, BAY86-5046);Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
35 A Pilot Safety and Tolerability Open-Label Study of Interferon Beta-1b in Combination With Tacrolimus in Patients Suffering From Multiple Sclerosis Who Have Failed Treatment With Approved Disease Modifying Agents Unknown status NCT00298662 Phase 2 Interferon beta-1b and Tacrolimus
36 Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease Unknown status NCT02649985 Phase 1, Phase 2 [F-18]PBR06
37 A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2 Hyperimmune caprine serum against HIV lysate
38 Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2 Erythropoietin
39 Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) Unknown status NCT01815632 Phase 2
40 Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT02308137 Phase 2 Domperidone
41 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2 Natalizumab
42 A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. Completed NCT01910259 Phase 2 Amiloride;Riluzole;Fluoxetine;Placebo
43 A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis Completed NCT02228213 Phase 2 Saline
44 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial Completed NCT00257855 Phase 2 Lamotrigine
45 A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase Completed NCT00086671 Phase 2 ABT-874/Human monoclonal antibody against IL-12;Placebo
46 Treatment of Multiple Sclerosis Using Over the Counter Inosine Completed NCT00067327 Phase 2 Inosine
47 A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
48 A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients Completed NCT03560739 Phase 2
49 A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple Sclerosis Completed NCT01324232 Phase 2 AVP-923;Placebo
50 A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Activity of Oral AB1010 Administered at 2 Dose Levels to Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Completed NCT01450488 Phase 2 masitinib;masitinib

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

40
Brain, B Cells, T Cells, Spinal Cord, Bone, Thyroid, Testes

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 1838)
# Title Authors PMID Year
1
[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. 61 54
20443171 2010
2
Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. 61 54
15645350 2004
3
Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. 61 54
9343121 1997
4
Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. 61
32345147 2020
5
A comprehensive analysis of antigen-specific autoimmune liver disease related autoantibodies in patients with multiple sclerosis. 61
32308974 2020
6
Retinal thickness as a potential biomarker of neurodegeneration and a predictor of early cognitive impairment in patients with multiple sclerosis. 61
32370626 2020
7
Serum antibodies to phosphatidylcholine in MS. 61
32518205 2020
8
The impact of RB1 genotype on incidence of second tumours in heritable retinoblastoma. 61
32434110 2020
9
RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome. 61
31944407 2020
10
Identifying the relevant determinants of MS related fatigue: The role of the clinical indicators of disease and personality. 61
32213466 2020
11
Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model. 61
32277856 2020
12
Scanning Probe Microscopy Analysis of Nonfullerene Organic Solar Cells. 61
32466653 2020
13
Ice-templating of chitosan/agarose porous composite hydrogel with adjustable water-sensitive shape memory property and multi-staged degradation performance. 61
32120129 2020
14
Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM). 61
31960250 2020
15
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. 61
32511687 2020
16
The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database. 61
32563531 2020
17
Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases. 61
32559700 2020
18
Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. 61
32515225 2020
19
Study Protocol of AMASIA, a Non-Interventional Study to Gain First Insights on SPMS Patients Treated With Siponimod in Clinical Routine. 61
32499214 2020
20
Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. 61
32552535 2020
21
Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany. 61
31832974 2020
22
Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? 61
32385712 2020
23
Steroid Fingerprint Analysis of Endangered Caspian Seal (Pusa caspica) through the Gorgan Bay (Caspian Sea). 61
32459473 2020
24
Estimating the Effect of Single-Point Mutations on Protein Thermodynamic Stability and Analyzing the Mutation Landscape of the p53 Protein. 61
32401507 2020
25
Streamline density and lesion volume reveal a postero-anterior gradient of corpus callosum damage in multiple sclerosis. 61
32170811 2020
26
Renal tumours in Australian children: 30 years of incidence, outcome and second primary malignancy data from the Australian Childhood Cancer Registry. 61
31943452 2020
27
Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer. 61
32084523 2020
28
Use of Specialized Pro-Resolving Mediators to Alleviate Cold Platelet Storage Lesion. 61
32478925 2020
29
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? No. 61
32334842 2020
30
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes. 61
32265072 2020
31
Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment. 61
32278541 2020
32
Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease through the Resolvin E1 and ChemR23 Axis. 61
32506925 2020
33
Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers. 61
32504180 2020
34
Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis. 61
32495237 2020
35
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. 61
32434867 2020
36
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: Multicenter study in Argentina. 61
32484381 2020
37
[Data on multiple sclerosis in Germany and their representation in the ambulatory registry NeuroTransData (NTD) network]. 61
32557466 2020
38
Longitudinal patterns of cortical thinning in multiple sclerosis. 61
32067281 2020
39
Incidence, prevalence and characteristics of MS in São Miguel, an island in the Atlantic. 61
32562908 2020
40
Symbol Digit Modalities Test: Greek Normative Data for the Oral and Written Version and Discriminative Validity in Patients with Multiple Sclerosis. 61
32385488 2020
41
Human health benefits of very-long-chain polyunsaturated fatty acids from microalgae. 61
32389760 2020
42
Characteristics of chlorinated and brominated polycyclic aromatic hydrocarbons in the Pearl River Estuary. 61
32544675 2020
43
A protein palmitoylation cascade regulates microtubule cytoskeleton integrity in Plasmodium. 61
32395856 2020
44
15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-Lipoxygenase-2 in biosynthesis of resolvin D5. 61
32404334 2020
45
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. 61
31951777 2020
46
Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis. 61
31982413 2020
47
The transitional phase of multiple sclerosis: Characterization and conceptual framework. 61
32535501 2020
48
N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer's disease. 61
32398649 2020
49
Receptors for pro-resolving mediators are increased in Alzheimer's disease brain. 61
31912564 2020
50
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis. 61
32370288 2020

Variations for Secondary Progressive Multiple Sclerosis

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 S100B RORC MMP9 IL4 IL17A IL10
2
Show member pathways
13.82 NGF IL4 IL17A IL10 CXCR3 CXCL10
3
Show member pathways
13.55 NGF IL4 IL17A IL10 IFNG IFNB1
4
Show member pathways
13.42 MMP9 CXCR3 CXCL10 CCR5 CCR3 CCR2
5
Show member pathways
13.37 NGF IL4 IL17A IL10 IFNG IFNB1
6
Show member pathways
13.29 RORC MMP9 IL4 IL17A IL10 IFNG
7
Show member pathways
13.22 NGF IL4 IL17A IL10 CXCR3 CXCL10
8
Show member pathways
13.05 MMP9 IL10 IFNG IFNB1 CXCL10 CCL2
9
Show member pathways
12.89 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
10
Show member pathways
12.86 IL4 IL17A IL10 IFNG CD40LG CCL21
11
Show member pathways
12.84 NGF IL4 IL17A IL10 CXCR3 CXCL10
12
Show member pathways
12.62 IL4 IL17A IL10 IFNG CD40LG CCR5
13
Show member pathways
12.6 RORC IL4 IL17A IL10 IFNG
14
Show member pathways
12.6 RORC IL17A IL10 IFNG CCL2
15 12.57 IL4 IL17A IL10 IFNG CXCL10 CD40LG
16
Show member pathways
12.47 IL4 IL10 IFNG IFNB1 CCR5 CCR2
17
Show member pathways
12.37 RORC MMP9 IL4 IL17A IFNG CXCL10
18
Show member pathways
12.33 IL4 IFNG CCL2 ALB
19
Show member pathways
12.31 NGF IL4 IL17A IL10 IFNG IFNB1
20
Show member pathways
12.3 IL10 CXCR3 CXCL10 CCR5 CCR3 CCR2
21
Show member pathways
12.29 IL4 IL10 IFNG CD40LG CCR5
22
Show member pathways
12.2 IL4 IFNG IFNB1 CXCL10
23 12.04 RORC MMP9 IL4 IL17A IL10 CCL2
24 12.01 IL4 IL10 IFNG CCR3
25 11.99 MMP9 IFNB1 CXCL10 CCL2
26
Show member pathways
11.96 RORC IL17A IL10 IFNG
27
Show member pathways
11.88 RORC IL4 IL17A IFNG
28 11.81 RORC IL4 IL17A IL10 IFNG CXCR3
29
Show member pathways
11.79 NGF CD40LG BDNF
30 11.77 S100B NGF BDNF
31
Show member pathways
11.75 IL4 IFNG CD40LG
32 11.74 IL10 IFNG IFNB1
33 11.72 MMP9 IL4 CCR3 CCR2 CCL2
34
Show member pathways
11.66 MMP9 IFNG CD40LG
35 11.66 IL4 IL10 CD40LG
36 11.58 IL10 IFNG CD40LG CCL2
37 11.54 IFNG CCR2 CCL2
38 11.51 IL4 IL10 IFNG
39 11.49 IL4 IL10 CXCL10 CCR5 CCR2 CCL2
40 11.41 IFNG IFNB1 CXCL10
41 11.38 MMP9 CD40LG CCR2 CCL2
42 11.35 IL4 IFNG CD40LG
43 11.33 IL4 IL17A IFNG
44 11.33 IL4 IL10 IFNG IFNB1
45 11.3 MMP9 MBP IL4 IFNG CXCL10 CCR2
46 11.25 MMP9 IFNG CCR3 CCL2
47 11.22 IL4 IL10 IFNG
48 11.03 NGF IL4 IL17A IL10 CXCL10 CD40LG

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.8 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
2 extracellular region GO:0005576 9.8 S100B NGF MMP9 IL4 IL17A IL10
3 external side of plasma membrane GO:0009897 9.7 IL17A CXCR3 CXCL10 CD40LG CCR5 CCR3
4 extracellular space GO:0005615 9.47 S100B NGF MMP9 IL4 IL17A IL10

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 IL4 IL10 CXCR3 CXCL10 CD40LG CCR5
2 G protein-coupled receptor signaling pathway GO:0007186 10.19 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
3 negative regulation of apoptotic process GO:0043066 10.02 NGF MMP9 IL4 IL10 CD40LG BDNF
4 cell-cell signaling GO:0007267 9.97 IL17A CXCL10 CCR5 CCL21
5 cellular response to lipopolysaccharide GO:0071222 9.94 IL10 CXCL10 CCR5 CCL2
6 cell surface receptor signaling pathway GO:0007166 9.93 IFNG IFNB1 CXCR3 CXCL10 CCR5 CCL2
7 positive regulation of cytosolic calcium ion concentration GO:0007204 9.91 CXCR3 CCR5 CCR3 CCR2
8 inflammatory response GO:0006954 9.91 IL17A CXCR3 CXCL10 CD40LG CCR5 CCR3
9 negative regulation of neuron apoptotic process GO:0043524 9.9 NGF IL10 CCL2 BDNF
10 chemotaxis GO:0006935 9.87 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
11 memory GO:0007613 9.86 S100B NGF BDNF
12 cellular response to interleukin-1 GO:0071347 9.85 IL17A CCL21 CCL2
13 cell chemotaxis GO:0060326 9.85 CXCR3 CCR5 CCR3 CCR2 CCL21 CCL2
14 neutrophil chemotaxis GO:0030593 9.84 CXCL10 CCL21 CCL2
15 calcium-mediated signaling GO:0019722 9.84 CXCR3 CCR5 CCR3 CCR2
16 B cell differentiation GO:0030183 9.83 IL4 IL10 IFNB1 CD40LG
17 cellular defense response GO:0006968 9.81 CCR5 CCR3 CCR2
18 humoral immune response GO:0006959 9.8 IFNG IFNB1 CCR2 CCL2
19 monocyte chemotaxis GO:0002548 9.79 CCR2 CCL21 CCL2
20 positive regulation of interleukin-6 secretion GO:2000778 9.77 MBP IL17A IFNG
21 B cell proliferation GO:0042100 9.75 IL10 IFNB1 CD40LG
22 JAK-STAT cascade GO:0007259 9.74 IFNG CCR2 CCL2
23 positive regulation of tumor necrosis factor biosynthetic process GO:0042535 9.72 IL17A IFNG CCR2
24 chemokine-mediated signaling pathway GO:0070098 9.7 CXCR3 CXCL10 CCR5 CCR3 CCR2 CCL21
25 dendritic cell chemotaxis GO:0002407 9.69 CCR5 CCR2 CCL21
26 T cell chemotaxis GO:0010818 9.68 CXCR3 CXCL10
27 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.67 IL4 IL10
28 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.67 MBP IL10
29 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.66 IL17A IFNG
30 positive regulation of collateral sprouting GO:0048672 9.65 NGF BDNF
31 positive regulation of receptor binding GO:1900122 9.65 MMP9 BDNF
32 cytokine-mediated signaling pathway GO:0019221 9.65 RORC MMP9 IL4 IL17A IL10 IFNB1
33 type 2 immune response GO:0042092 9.64 IL4 IL10
34 positive regulation of cellular respiration GO:1901857 9.63 IL4 IFNG
35 neuroinflammatory response GO:0150076 9.62 IL4 IFNG
36 positive regulation of interleukin-23 production GO:0032747 9.62 IL17A IFNG
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL4 IL10 IFNG
38 regulation of isotype switching GO:0045191 9.58 IL4 IL10
39 positive regulation of NMDA glutamate receptor activity GO:1904783 9.58 IFNG CCR2 CCL2
40 immune response GO:0006955 9.44 MBP IL4 IL17A IL10 IFNG CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 S100B RORC NGF MMP9 MBP IL4
2 signaling receptor binding GO:0005102 9.89 S100B NGF CXCL10 CCL2 BDNF
3 growth factor activity GO:0008083 9.71 NGF IL4 IL10 BDNF
4 chemokine activity GO:0008009 9.63 CXCL10 CCL21 CCL2
5 chemokine binding GO:0019956 9.62 CXCR3 CCR5 CCR3 CCR2
6 C-C chemokine binding GO:0019957 9.56 CXCR3 CCR5 CCR3 CCR2
7 CCR2 chemokine receptor binding GO:0031727 9.48 CCR2 CCL2
8 C-C chemokine receptor activity GO:0016493 9.46 CXCR3 CCR5 CCR3 CCR2
9 nerve growth factor receptor binding GO:0005163 9.43 NGF BDNF
10 cytokine activity GO:0005125 9.28 IL4 IL17A IL10 IFNG IFNB1 CXCL10
11 chemokine receptor activity GO:0004950 9.26 CXCR3 CCR5 CCR3 CCR2

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....